Global Renin-Inhibitors Sales Market Report 2023
SKU ID :QYR-22289313 | Published Date: 02-Jan-2023 | No. of pages: 113Description
Market Analysis and Insights: Global Renin-Inhibitors Market
Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Due to the COVID-19 pandemic, the global Renin-Inhibitors market size is estimated to be worth US$ 91 million in 2022 and is forecast to a readjusted size of US$ 145 million by 2029 with a CAGR of 6.8% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, 150mg/Tablet accounting for % of the Renin-Inhibitors global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Age below 45 segment is altered to an % CAGR throughout this forecast period.
Global Renin-Inhibitors main player is Noden Pharma, etc. Noden Pharma is dominating the market. USA is the largest market, with a share nearly 45%.
Global Renin-Inhibitors Scope and Market Size
The global Renin-Inhibitors market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Renin-Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
150mg/Tablet
300mg/Tablet
Segment by Application
Age below 45
Age 45-55
Age 55-65
Age above 65
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Novartis
Noden Pharma
Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Due to the COVID-19 pandemic, the global Renin-Inhibitors market size is estimated to be worth US$ 91 million in 2022 and is forecast to a readjusted size of US$ 145 million by 2029 with a CAGR of 6.8% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, 150mg/Tablet accounting for % of the Renin-Inhibitors global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Age below 45 segment is altered to an % CAGR throughout this forecast period.
Global Renin-Inhibitors main player is Noden Pharma, etc. Noden Pharma is dominating the market. USA is the largest market, with a share nearly 45%.
Global Renin-Inhibitors Scope and Market Size
The global Renin-Inhibitors market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Renin-Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
150mg/Tablet
300mg/Tablet
Segment by Application
Age below 45
Age 45-55
Age 55-65
Age above 65
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Novartis
Noden Pharma
TOC
Tables & Figures
Companies
- PRICE
-
$4000$8000$6000Buy Now